It is believe that ragweed is the primary cause of autumn allergies and 87% of patients with ragweed allergy suffer rhinoconjunctivitis. ToleroMune Ragweed is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of ragweed allergy. This study will look at the efficacy, safety and tolerability of two doses of ToleroMune Ragweed in ragweed allergic subjects following challenge with ragweed in an EEC.
This study is designed as a randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and tolerability of ToleroMune Ragweed in ragweed allergic subjects with allergic rhinoconjunctivitis,subjects may also have controlled asthma. The efficacy of ToleroMune Ragweed will be explored in subjects using an(Environmental Exposure Chamber)EEC. The study will consist of 3 study periods. In Period 1, Screening will be performed up to a maximum of 12 weeks before randomisation and may consist of one or two visits to the clinic, at the Investigator's discretion. Baseline Challenge will consist of 4 visits to the EEC at least 3 days before randomisation. In Period 2, subjects in each cohort complying with the inclusion/exclusion criteria will be randomised to one of five groups and will receive treatment every 2 weeks (±2 days) for 14 weeks. In Period 3, Post Treatment Challenge will consist of 4 visits to the EEC 18-22 weeks after the first administration in the treatment period and assessments will be performed identical to those at the baseline challenge. Follow-up will be conducted 3-10 days after PTC.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
275
Intradermal injection 1 x8 administrations 2 weeks apart
Intradermal injection, 1x8 administrations 2 weeks apart
KGK Synergize Inc.
London, Ontario, Canada
Cetero Research
Mississauga, Ontario, Canada
Total Rhinoconjunctivitis Symptom Score
Time frame: Upto 22 weeks
Symptom scores for ocular and nasal symptoms
Time frame: Upto 22 weeks
Acoustic Rhinometry
Time frame: Upto 22 weeks
Skin prick testing
Time frame: Baseline and final follow up
Ragweed specific IgE
Time frame: At baseline and at follow up
Ragweed specific IgA
Time frame: At baseline and follow up
Ragweed specific IgG4
Time frame: At baseline and at follow up
Adverse Events
Time frame: Upto 23 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.